Moreover, in a recent clinical study, a cohort of MM patients that received a bortezomib-based chemotherapy regimen was tested for their neurological, neurophysiological and inflammatory status (CD4, CD8 T cell subpopulations, CD4+ sub-populations, pro-inflammatory interleukins profile). This evidence concerns the gene CD8A and Miyoshi myopathy.